A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Inclusion Criteria: for subjects with impaired renal function * Able to comprehend and willing to sign an informed consent form (ICF) * 18-70 years of age. * 19 kg/m2\<BMI \<19-28 kg/m2 * eGFR (MDRD equation) for mild impaired renal function: 60-89 mL/min/1.73 m2 eGFR (MDRD equation) for moderate impaired renal function: 30-59 mL/min/1.73 m2 * In good health, except for kidney disease and complications, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG; * Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test; for healthy subjects: * Able to comprehend and willing to sign an informed consent form (ICF) * 18-70 years of age. * 19 kg/m2\<BMI \<19-28 kg/m2 * eGFR (MDRD equation) for mild impaired renal function: ≥90mL/min/1.73 m2 * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG; * Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test; Exclusion Criteria: for subjects with renal impairment * Renal allograft recipients; * Need hemodialysis during study; * Uroclepsia or anuria; * Allergic to apatinib or ingredients; * History of heart disease in 12 months before study; * Coagulation disorders; * Hypertension and could not be controlled with hypotensor; * With hepatic or archenteric disease; * Participate in blood donation within 3 months before screening and donate blood volume ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month prior dosing. * Take any clinical trial drugs within 3 months prior dosing; * Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days before dosing; * Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit = 285 mL of beer, or 100mL of wine), or take ≥5 cigarettes; * Positive in urine drug test; * Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection; * Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or grapefruit-containing products from 48 hours before dosing to the end of the study; * The investigator believes that the subjects are not eligible to participate in this trial. for healthy subjects: * Renal allograft recipients; * Allergic to apatinib or ingredients; * History of heart disease in 12 months before study; * Coagulation disorders; * Hypertension and could not be controlled with hypotensor; * With hepatic or archenteric disease; * Participate in blood donation within 3 months before screening and donate blood volume ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month prior dosing. * Take any clinical trial drugs within 3 months prior dosing; * Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days before dosing; * Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit =285 mL of beer, or 100mL of wine), or take ≥5 cigarettes; * Positive in urine drug test; * Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection; * Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or grapefruit-containing products from 48 hours before dosing to the end of the study; * The investigator believes that the subjects are not eligible to participate in this trial.